M. Mentze

Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial.

J. Blohmer, S. Kümmel, W. Lichtenegger, 2014, Anticancer research.

The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer

J. Sehouli, D. Dragun, E. Braicu, 2018, AntiCancer Research.

Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)

A. Kopp-Schneider, J. Sehouli, I. Braicu, 2017, Journal of Ovarian Research.

Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer.

W. Lichtenegger, J. Sehouli, K. Bühling, 2009, Anticancer research.

HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium

R. Zeillinger, I. Vergote, N. Concin, 2014, OncoTargets and therapy.

Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.

J. Blohmer, S. Kümmel, W. Lichtenegger, 2013, Cytokine.

hiF 1 α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVcaD consortium

R. Zeillinger, I. Vergote, N. Concin, 2014 .